NCT05633602 2026-04-17
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
SWOG Cancer Research Network
Phase 3 Active not recruiting
Clinical Trials
30 trialsNCT07288034 2026-04-15
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
Phase 2 Recruiting
NCT07526961 2026-04-14
Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland
Bristol-Myers Squibb
Completed
NCT03939481 2026-04-13
Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer
SWOG Cancer Research Network
Active not recruiting
NCT07226999 2026-04-08
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Pfizer
Phase 2/3 Recruiting
NCT07476287 2026-04-08
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
Pfizer
Phase 2 Recruiting
NCT04302025 2026-04-03
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Genentech, Inc.
Phase 2 Recruiting
NCT07507188 2026-04-02
INSTAR
Yonsei University
Phase 2 Not yet recruiting
NCT07354061 2026-04-01
TD-ENSEMBLE
Tang-Du Hospital
Phase 1/2 Recruiting
NCT02122185 2026-03-27
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Chicago
Phase 2 Completed
NCT06538038 2026-03-27
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
PrECOG, LLC.
Recruiting
NCT07477808 2026-03-23
Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 3 Not yet recruiting
NCT05143970 2026-03-20
CHANCES
Institut Paoli-Calmettes
Phase 1 Recruiting
NCT06738160 2026-03-20
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
Fudan University
Phase 2 Recruiting
NCT07472478 2026-03-16
GIVEN
Guangdong Provincial People's Hospital
Phase 2 Not yet recruiting
NCT07472647 2026-03-16
SYS6090 Combination Therapy in Advanced Lung Cancer
Shanghai JMT-Bio Inc.
Phase 1/2 Not yet recruiting
NCT05378334 2026-03-10
Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients
Guangzhou University of Traditional Chinese Medicine
Phase NA Recruiting
NCT06385262 2026-03-06
TOP 2301: Neoadjuvant Chemo for NSCLC
Duke University
Phase 2 Suspended
NCT07452003 2026-03-05
An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC
Peking Union Medical College Hospital
Phase NA Recruiting
NCT06719700 2026-03-03
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT03774732 2026-02-25
NIRVANA-LUNG
UNICANCER
Phase 3 Active not recruiting
NCT04798664 2026-02-25
Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening
Abramson Cancer Center at Penn Medicine
Phase NA Completed
NCT07425795 2026-02-23
Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer
Chongqing University Cancer Hospital
Phase 2 Recruiting
NCT07408635 2026-02-13
IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT07398937 2026-02-10
ECTOP-1036
Fudan University
Phase 2 Recruiting
NCT04297605 2026-02-09
Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
University of Rochester
Phase 1 Recruiting
NCT06610734 2026-02-09
SKY
Sichuan University
Phase 2 Recruiting
NCT06018376 2026-02-06
LUDICAS
Fundación GECP
Completed
NCT05488626 2026-02-05
ARTIA-Lung
Varian, a Siemens Healthineers Company
Phase NA Withdrawn
NCT07358676 2026-01-22
A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting